Author

V. Flore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

S. Haas· 2 shared A. Akalin· 1 shared A. Milojkovic· 1 shared A.-H. Maag· 1 shared B. Uyar· 1 shared C. Buske· 1 shared C. Chen· 1 shared C. Flotho· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. Haas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Oncogene inactivation-induced senescence facilitates tumor relapse

P. Schmitt, K. Hoenig, M. T. Norcia, M. F. Nogueira, V. Flore, I. S. Vesperinas, M. Villoro-Agud, L. Peng, Z. Safyuerek, M. Tariq, A. Milojkovic, K. Anders, E. Schroeck, S. Sauer, B. Uyar, , T. Blankenstein

This study shows that oncogene inactivation-induced senescence both limits tumor growth and promotes relapse by creating a pro-recurrence microenvironment.

Nature Communications · Jul 15, 2026Peer-reviewedCancer Biology

Oncogenic RAS-Pathway Activation Drives Oncofetal Reprogramming and Creates Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia

M. Hartmann, M. Schoenung, J. Rajak, V. Maurer, L. Hai, K. Bauer, M. Hakobyan, S. Staeble, J. Langstein, L. Jardine, R. Roelz, S. Bohler, E. Khabirova, A.-H. Maag, D. Vonficht, , D. B. Lipka

This study identifies oncofetal reprogramming in juvenile myelomonocytic leukemia, linking RAS-pathway activation to fetal gene expression and revealing CD52 as a therapeutic target.

bioRxiv · Oct 27, 2023Cancer Biology